Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
-$0.06 today
- Market cap
- $784.28M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
Volume 4.75M
Average 3.58M
ARDX Interest Expense
Cost of servicing the company's debt during the period.
Ardelyx, Inc.NASDAQ: ARDX
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense grows, but more slowly than its trailing trend
Q1 FY2026 interest expense of $6.92M rose 10.4% year over year, behind the +30.3% change in trailing-twelve-month interest expense. Sequentially, it fell 8.7% from the prior quarter. Over 3 fiscal years it compounded at +77.6% a year.
Context
- Interest expense amounted to 7.0% of revenue in FY2025, up 0.9 pp from a year earlier.
- Interest expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.4% toward the trailing-twelve-month pace of +30.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 28.4M USD
- Year-over-year change
- +41.3%
- 4-year CAGR
- +58.5%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.4M | +41.3% |
| FY2024 | 2024-12-31 | 20.09M | +126.4% |
| FY2023 | 2023-12-31 | 8.87M | +74.9% |
| FY2022 | 2022-12-31 | 5.07M | +12.7% |
| FY2021 | 2021-12-31 | 4.5M | — |
Interest Expense vs competitors
How ARDX compares with its peers on the latest reported figures
- ARDX's LTM Mar 2026 interest expense of $29.05M is the highest of the 5 companies compared; the peer median is $6.29M.
- Its year-over-year change of +30.3% is the highest of 3, against a peer median of -28.4%.
- Interest expense amounts to 6.8% of revenue for ARDX, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.05M | +30.3% | +77.6% | 6.8% | |
| LTM Mar 2026 | $28.66M | -6.8% | +27.3% | 9.1% | |
| LTM Mar 2026 | $11.72M | -50.0% | +15.5% | 5.0% | |
| LTM Mar 2026 | $866K | — | — | 4.3% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ARDX) | $6.29M | -28.4% | +21.4% | 5.0% | |
Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.1M | 52.16M | 124.46M | 333.62M | 407.32M |
| Cost of Revenue | 1M | 4.12M | 17.8M | 50.56M | 42.6M |
| Gross Profit | 9.1M | 48.04M | 106.66M | 283.06M | 364.72M |
| Gross Margin | 90.1% | 92.1% | 85.7% | 84.8% | 89.5% |
| Research & Development | 91.14M | 35.2M | 35.54M | 52.32M | 68.47M |
| Selling, General & Admin | 72.3M | 76.6M | 134.4M | 258.69M | 337.23M |
| Operating Expenses | 163.44M | 111.8M | 169.94M | 311.01M | 405.7M |
| Depreciation & Amortization | 2.81M | 1.14M | 1.29M | 2.06M | 3.06M |
| EBITDA | (150.85M) | (60.98M) | (55.35M) | (16.71M) | (29.17M) |
| EBITDA Margin | -1494.0% | -116.9% | -44.5% | -5.0% | -7.2% |
| Operating Income | (154.35M) | (63.76M) | (63.28M) | (27.95M) | (40.98M) |
| Operating Margin | -1528.6% | -122.2% | -50.8% | -8.4% | -10.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.5M | 5.07M | 8.87M | 20.09M | 28.4M |
| Other Income / Expenses | (3.82M) | (3.44M) | (2.24M) | (10.92M) | (19.65M) |
| Income Before Tax | (158.16M) | (67.2M) | (65.52M) | (38.87M) | (60.63M) |
| Pre-Tax Margin | -1566.4% | -128.8% | -52.6% | -11.7% | -14.9% |
| Income Tax Expense | 4K | 8K | 547K | 266K | 969K |
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Net Margin | -1566.5% | -128.9% | -53.1% | -11.7% | -15.1% |
| EPS (Basic) | (1.52) | (0.42) | (0.30) | (0.17) | (0.26) |
| EPS (Diluted) | (1.52) | (0.42) | (0.30) | (0.17) | (0.26) |
| Weighted Avg Shares | 104.21M | 158.69M | 219.33M | 235.23M | 241.03M |
| Weighted Avg Shares (Diluted) | 104.21M | 158.69M | 219.33M | 235.23M | 241.03M |
Ardelyx, Inc.
NASDAQ:ARDX
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.